NCT06610799View on ClinicalTrials.gov

Study of IBI363 in Patients with Advanced First-line Gastric Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2026

Conditions
IBI363 + Chemotherapy
Interventions
DRUG

IBI363

IBI363 Q3W Oxaliplatin 130 mg/m2，IV，Q3W, Capecitabine ,1000mg/ m2，PO，Bid，d1-14，Q3W

Trial Locations (1)

310000

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Xiangdong Cheng

OTHER